Blood Culture–Negative Endocarditis (BCNE)
Definition
Blood culture–negative endocarditis (BCNE) is IE without positive blood cultures. It accounts for up to 30% of all IE cases and is associated with worse outcomes than culture-positive IE due to the inability to provide pathogen-directed antimicrobial therapy. There are two distinct clinical scenarios: (1) prior antibiotic exposure before blood culture collection — the most common cause; (2) infection with fastidious or nonculturable microorganisms in patients without prior antibiotic exposure.
Key Concepts
Causes and Clinical Profile
Scenario 1: Prior Antibiotic Exposure (most common)
- Most common organisms suppressed: methicillin-susceptible staphylococci, streptococci, enterococci
- Clinical presentation: acute or subacute depending on the organism
- Approach: comprehensive review of antibiotic type, timing, duration, route, dosage before cultures; empiric coverage targeting above organisms sources/BCNE-AHA-2025 (rating: high)
Scenario 2: Fastidious/Nonculturable Organisms (minority)
- More likely subacute or chronic presentation
- Requires expanded laboratory testing beyond routine blood cultures
- Epidemiological history critical: animal exposure, travel, occupation, housing status sources/BCNE-AHA-2025 (rating: high)
Diagnostic Algorithm (Step-by-Step)
- Obtain minimum 2–3 blood culture sets (8–10 mL/bottle, ≥40 mL total) before antibiotics
- Start empiric antibiotics after cultures drawn; review prior antibiotic history thoroughly
- If cultures negative at 72 hours: expand to
- Prolonged blood culture incubation (already sampled)
- Serology: C. burnetii phase I IgG, Bartonella spp (+ Brucella if endemic)
- Metagenomic shotgun sequencing on plasma/whole blood (collect early and store; submit at 72h if conventional workup negative)
- Surgery (if indicated): excised tissue for cultures + pathology + PCR ± metagenomics
- Advanced imaging: 18F-FDG PET/CT or WBC SPECT/CT if TEE inconclusive in ≥possible IE
sources/BCNE-AHA-2025 (rating: high)
Metagenomic Next-Generation Sequencing (mNGS)
- Shotgun metagenomics detects microbial DNA longer than conventional cultures in antibiotic-exposed patients
- Proactive collection recommended: store specimen, submit at 72h if conventional workup negative
- Turnaround time (shipping + processing + analysis) must be factored in before ordering
- Caution: risk of false-positives and contaminants; requires infectious diseases + microbiology expert interpretation
- Under 2023 Duke-ISCVID criteria: only C. burnetii, Bartonella spp, and T. whipplei from metagenomics fulfil major criterion; others (e.g., Brucella, N. gonorrhoeae) that are not blood commensals are likely clinically reliable in compatible presentation
- No universally validated DNA quantification cutoff; interpretation contingent on pathogen-specific factors, antibiotic exposure, and sequencing sensitivity sources/BCNE-AHA-2025 (rating: high)
Fastidious Pathogen–Specific Management
Coxiella burnetii (Q Fever Endocarditis)
- Exposure: livestock/farm proximity (risk persists years after epizootic); most patients do NOT recall livestock contact
- Increased risk: congenital heart defects, prosthetic valves/implants, immunocompromised
- Diagnosis: phase I IgG >1:800 (rare cases have lower titres); PCR; tissue IHC; G6PD exclusion before hydroxychloroquine
- Treatment: doxycycline 100 mg q12h + hydroxychloroquine 200 mg q8h OR + quinolone; ≥18 months
- Monitoring serology: ≥4-fold phase I IgG decline (to <1:200) expected at cure; persistently elevated titres (>1:1024) despite clinical improvement does NOT mandate continued treatment — individualise; prosthetic material may require prolonged/lifelong therapy sources/BCNE-AHA-2025 (rating: high)
Bartonella spp (B. henselae, B. quintana)
- Transmission: B. henselae via cat scratch/flea feces; B. quintana via human body louse
- Social risk factors: homelessness, housing instability, communities without running water → always ask housing and animal exposure history
- Bartonellosis is now a major cause of BCNE
- Diagnosis: serology; targeted PCR whole blood; metagenomics; tissue culture (special conditions, ≥2 wk incubation)
- Treatment: doxycycline (preferred) or azithromycin 12 weeks + rifampin 6 weeks; gentamicin avoided due to risk of immune complex–mediated glomerulonephritis sources/BCNE-AHA-2025 (rating: high)
Tropheryma whipplei (Whipple Disease)
- Exposure: rural/soil/animal occupational; constitutional symptoms (fever, fatigue, weight loss, arthralgias, diarrhoea, cognitive impairment)
- Increasingly identified with molecular advances; now a major criterion in 2023 Duke-ISCVID
- Diagnosis: IHC tissue; targeted PCR; metagenomics; intestinal biopsy (PAS stain + IHC)
- Treatment: IV penicillin G or ceftriaxone ×4 weeks (initial); then TMP/SMX ≥11 months (if sulfa allergy: doxycycline + hydroxychloroquine)
- Awareness: Jarisch-Herxheimer reaction risk (especially with penicillin G); higher clinical failure/relapse rates sources/BCNE-AHA-2025 (rating: high)
Mycobacterium chimaera
- Context: large multicontinental outbreak from contaminated heater-cooler devices in cardiopulmonary bypass; estimated 156–282 cases/100,000/year before preventive measures
- Presentation: delayed-onset prosthetic valve BCNE; resembles mechanical prosthesis dehiscence → often missed on histological analysis
- Diagnosis: mycobacterial blood/valve cultures; species-specific PCR; metagenomics; pathology
- Treatment: susceptibility-guided ≥24 months + surgical intervention; yearly PET/CT until complete metabolic resolution at infected sites sources/BCNE-AHA-2025 (rating: high)
Fungal Endocarditis
- Risk: IVDU, intracardiac devices, immunosuppression, prosthetic valves
- Diagnosis: prolonged blood culture incubation; β-D-glucan; galactomannan; PCR (Candida, Aspergillus); metagenomics
- Empiric antifungal NOT started when suspected; initiate when indirect clues available (elevated β-D-glucan/galactomannan) given high mortality without early treatment
- Early cardiac surgery + excision of infected tissue critical
- Candida without surgery: high-dose echinocandin ≥6 weeks + oral azoles ≥2 years can achieve >50% success in inoperable cases
- Aspergillus mortality >80% in literature (>95% without cardiac surgery) sources/BCNE-AHA-2025 (rating: high)
Brucella spp
- Serological challenge: early testing or blocking antibodies → false-negatives; agglutination tests unreliable in chronic/complicated/neurologic cases
- Cross-reactivity: false-positives with E. coli O157, F. tularensis, Moraxella phenylpyruvica, Y. enterocolitica, certain Salmonella serotypes, V. cholerae vaccine recipients
- Relapse rate 5–15%; management: doxycycline + rifampin (rifampin resistance emerging); >1 year chronic brucellosis → extended antibiotic therapy provides minimal benefit sources/BCNE-AHA-2025 (rating: high)
Empiric Antibiotic Regimens
No consensus; significant US vs European variation due to antibiotic availability, organism prevalence, valve type:
| Scenario | US (AHA 2015 basis) | European (ESC 2023 basis) |
|---|---|---|
| BCNE prior antibiotics (NVE) | Vancomycin ± ceftriaxone | Amoxicillin + cefazolin (France preferred) |
| BCNE prior antibiotics (PVE) | Vancomycin ± ceftriaxone ± rifampin | Vancomycin + gentamicin + rifampin |
| BCNE no prior antibiotics (fastidious coverage) | Add doxycycline ± rifampin | Add doxycycline ± rifampin |
- Transition to oral therapy (POET criteria) reasonable once stable with confirmed susceptible pathogen
- Infectious diseases specialist consultation mandatory sources/BCNE-AHA-2025 (rating: high)
Nonbacterial Thrombotic Endocarditis (NBTE)
- NBTE (marantic endocarditis) is an important noninfectious differential in BCNE
- Clinical clue: symptomatic embolic events without fever or systemic infection signs
- Activated PTT prolongation suggests antiphospholipid syndrome or SLE
- Associated: advanced malignancy (most common), SLE, antiphospholipid antibody syndrome
- TEE > TTE for valvular abnormalities; CT + 18F-FDG PET/CT critical for cancer + NBTE diagnosis sources/BCNE-AHA-2025 (rating: high)
Prevention
- #1 prevention message: obtain ≥2 blood culture sets before starting antibiotics in any patient with suspected IE
- Educate patients with prosthetic valves / high-risk anatomy to seek blood cultures before antibiotics when febrile
- IE prophylaxis for at-risk dental/surgical procedures
- In low-resource settings: epidemiological risk factors must guide empiric therapy given diagnostic limitations sources/BCNE-AHA-2025 (rating: high)
Contradictions / Open Questions
- No RCT evidence for optimal empiric antibiotic regimen in BCNE; all recommendations are expert opinion with significant US-European divergence sources/BCNE-AHA-2025 (rating: high)
- Sensitivity of 18F-FDG PET/CT for native valve IE widely discrepant across studies (22% vs 76.8%), limiting its utility in native valve BCNE without prosthetic material sources/BCNE-AHA-2025 (rating: high)
- No validated microbial DNA quantification threshold for metagenomics in clinical practice; interpretation remains subjective and laboratory-dependent sources/BCNE-AHA-2025 (rating: high)
- BCNE rates are declining in some high-income countries; unclear whether this reflects molecular diagnostic advances, antimicrobial stewardship improvement, or changes in IE epidemiology sources/BCNE-AHA-2025 (rating: high)
Connections
- Related to concepts/Infective-Endocarditis — parent diagnosis framework; Duke-ISCVID criteria
- Related to concepts/Valvular-Heart-Disease — prosthetic valves are high-risk substrate for BCNE
- Related to entities/ATTR-Amyloidosis — infiltrative cardiomyopathy can mimic valvular vegetations
- Related to concepts/Cardiac-Amyloidosis-Imaging — differential diagnosis for valvular echogenic masses
- Related to entities/Atrial-Fibrillation — new-onset AF can be a complication of endocarditis